Login / Signup

Imiquimod 5% cream as a therapeutic option for extramammary Paget's disease.

Masahide SawadaJunji KatoToshiharu YamashitaAkihiro YonetaTokimasa HidaKohei HorimotoSayuri SatoHisashi Uhara
Published in: The Journal of dermatology (2017)
A wide local excision is the standard treatment for extramammary Paget's disease (EMPD), though this treatment often leads to permanent anogenital mutilation and functional impairment. The purpose of our study is to evaluate the efficacy and safety of the topical application of imiquimod 5% cream for non-invasive EMPD. We examined nine patients with EMPD. Eight of the nine patients were treated with imiquimod 5% cream three times per week for 16 weeks; one case was treated for 6 weeks. The response rate was 100% including five complete remissions. Local irritation was observed in three patients, which was controlled by a provisional withdrawal of the treatment. These results suggest that imiquimod 5% cream may be considered an alternative therapeutic option for the treatment of non-invasive EMPD.
Keyphrases
  • newly diagnosed
  • randomized controlled trial
  • prognostic factors
  • combination therapy
  • chronic kidney disease
  • patient reported outcomes
  • gestational age
  • study protocol
  • double blind
  • placebo controlled